Drug Details
General Information of the Drug (ID: DR5656) | ||||
---|---|---|---|---|
Name |
Loxoprofen
|
|||
Synonyms |
Loxoprofen; 68767-14-6; 2-(4-((2-Oxocyclopentyl)methyl)phenyl)propanoic acid; Loxoprofene; Loxoprofeno; Koloxo; Loxoprofenum; Loxoprofen [INN]; 2-[4-[(2-oxocyclopentyl)methyl]phenyl]propanoic acid; UNII-3583H0GZAP; 2-{4-[(2-oxocyclopentyl)methyl]phenyl}propanoic acid; MFCD00864331; CHEMBL19299; 3583H0GZAP; Loxoprofen sodium hydrate; CHEBI:76172; CS-600; sodium loxoprofen; Loxoprofen (INN); Oxeno; NCGC00015594-02; DSSTox_CID_25164; DSSTox_RID_80714; DSSTox_GSID_45164; Loxoprofene [French]; Loxoprofenum [Latin]; Loxoprofeno [Spanish]; yl]-propionic acid; CAS-68767-14-6; 2-[4-(2-Oxo-cyclopentylmethyl)-phen; Loxoprofen, solid; 80382-23-6; Lopac0_000677; SCHEMBL24423; C15H17NaO3; (+-)-p-((2-Oxocyclopentyl)methyl)hydratropic acid; DTXSID1045164; alpha-Methyl-4-[(2-oxocyclopentyl)methyl]benzeneacetic acid; HMS3262G15; HMS3885N16; Loxoprofen (low-melting polymorph); BCP10971; EBD24378; HY-B0578; Loxoprofen (high-melting polymorph); Tox21_110178; Tox21_500677; ANW-43655; BDBM50140320; s4682; AKOS015906359; Tox21_110178_1; AC-8108; AT-7141; CCG-204763; DB09212; GS-3193; LP00677; SDCCGSBI-0050656.P002; NCGC00015594-03; NCGC00015594-04; NCGC00015594-08; NCGC00094037-01; NCGC00094037-02; NCGC00261362-01; NCGC00263577-01; AC-15776; AK-72809; H883; SY113439; AB0012364; DB-055188; EU-0100677; FT-0641207; L0244; CS-600; CS600; CS 600; D08149; L 0664; M-9376; (+-)-((2-oxocyclopentyl)methyl)hydratropic acid; 767L146; A836244; SR-01000075955; Q-201324; Q-300011; Q2759348; SR-01000075955-1; 2-[4-[(2-Oxocyclopentyl)methyl]phenyl]propionic Acid; 2-(4-((2-Oxocyclopentyl)methyl)-phenyl)propanoic acid; 2-[4-(2-Oxo-cyclopentylmethyl)-phenyl]-propionic acid; 2-[4-(2-oxocyclopentan-1-ylmethyl)phenyl]propionic acid; 2-[4-(2-Oxocyclopentan-1-ylmethyl)phenyl]-propionic Acid; 2-[4-[(2-oxidanylidenecyclopentyl)methyl]phenyl]propanoic acid; Benzeneacetic acid, alpha-methyl-4-((2-oxocyclopentyl)methyl)-; Benzeneacetic acid, .alpha.-methyl-4-[(2-oxocyclopentyl)methyl]-
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Ankylosing spondylitis [ICD-11: FA92] | Phase 4 | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C15H18O3
|
|||
PubChem CID | ||||
Canonical SMILES |
CC(C1=CC=C(C=C1)CC2CCCC2=O)C(=O)O
|
|||
InChI |
1S/C15H18O3/c1-10(15(17)18)12-7-5-11(6-8-12)9-13-3-2-4-14(13)16/h5-8,10,13H,2-4,9H2,1H3,(H,17,18)
|
|||
InChIKey |
YMBXTVYHTMGZDW-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 68767-14-6
|
|||
ChEBI ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Glycine | Musa x paradisiaca | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vivo Model | Female Sprague-Dawley rats, weighing 200-250 g (10-12-week-old), were used in this study. | |||||
Experimental
Result(s) |
The combined administration of loxoprofen and glycine produced a synergistic inhibitory effect on the micturition reflex. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Prostaglandin G/H synthase 1 (COX-1) | Molecule Info | [3] | |
Prostaglandin G/H synthase 2 (COX-2) | Molecule Info | [3] | ||
BioCyc | Aspirin-triggered lipoxin biosynthesis | Click to Show/Hide | ||
2 | Aspirin triggered resolvin D biosynthesis | |||
3 | C20 prostanoid biosynthesis | |||
4 | Aspirin triggered resolvin E biosynthesis | |||
KEGG Pathway | Arachidonic acid metabolism | Click to Show/Hide | ||
2 | Metabolic pathways | |||
3 | NF-kappa B signaling pathway | |||
4 | VEGF signaling pathway | |||
5 | TNF signaling pathway | |||
6 | Retrograde endocannabinoid signaling | |||
7 | Serotonergic synapse | |||
8 | Ovarian steroidogenesis | |||
9 | Oxytocin signaling pathway | |||
10 | Regulation of lipolysis in adipocytes | |||
11 | Leishmaniasis | |||
12 | Pathways in cancer | |||
13 | Chemical carcinogenesis | |||
14 | MicroRNAs in cancer | |||
15 | Small cell lung cancer | |||
16 | Platelet activation | |||
NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
2 | TSH Signaling Pathway | |||
3 | IL4 Signaling Pathway | |||
4 | TGF_beta_Receptor Signaling Pathway | |||
5 | IL5 Signaling Pathway | |||
Panther Pathway | Endothelin signaling pathway | Click to Show/Hide | ||
2 | Inflammation mediated by chemokine and cytokine signaling pathway | |||
3 | Toll receptor signaling pathway | |||
4 | CCKR signaling map ST | |||
Pathwhiz Pathway | Arachidonic Acid Metabolism | Click to Show/Hide | ||
Pathway Interaction Database | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | Click to Show/Hide | ||
2 | S1P1 pathway | |||
3 | C-MYB transcription factor network | |||
4 | Signaling mediated by p38-alpha and p38-beta | |||
5 | Calcium signaling in the CD4+ TCR pathway | |||
WikiPathways | Prostaglandin Synthesis and Regulation | Click to Show/Hide | ||
2 | Arachidonic acid metabolism | |||
3 | Aryl Hydrocarbon Receptor | |||
4 | Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | |||
5 | Spinal Cord Injury | |||
6 | Integrated Pancreatic Cancer Pathway | |||
7 | Eicosanoid Synthesis | |||
8 | Selenium Micronutrient Network | |||
9 | Phase 1 - Functionalization of compounds |